Division of Pediatric Surgical Oncology, Department of Pediatric Surgery, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
J Vasc Interv Radiol. 2011 Mar;22(3):279-86. doi: 10.1016/j.jvir.2010.11.025.
To evaluate the therapeutic effect of preoperative transcatheter arterial chemoembolization (TACE) combined with short-term systematic chemotherapy in the treatment of advanced Wilms tumor.
This was a retrospective study on 66 patients with unilateral advanced Wilms tumor, age 5 months to 11 years (median, 2.9 years; 30 boys and 36 girls), treated at our institution between 1995 and 2007. Characteristics of the patient population were maximal tumor diameter > 10 cm, or involvement of periaortic lymph nodes, or inferior vena cava invasion, or distal metastasis, or tumor with anaplastic histology. Patients were divided into three groups. Twenty patients were treated with conventional preoperative chemotherapy (PC group) using vindesine, actinomycin D, and pirarubicin for 4 weeks; 21 patients were treated in the TACE group with preoperative renal arterial chemoembolization using Lipiodol-pirarubicin-vindesine emulsion; and 25 patients were treated with preoperative chemoembolization combined with short-term systematic chemotherapy (T+S) for 2 weeks.
No drug-induced cardiotoxicity, nephrotoxicity, or hepatic dysfunction was observed. Complete surgical removal of the tumor was achieved in 12 (65.0%), 17 (80.9%), and 22 (88.0%) patients in the PC, TACE, and T+S groups, respectively (T+S group vs PC group, P = .030). The 2-year relapse-free survival rates were 65.0%, 80.9%, and 100.0% in the PC, TACE, and T+S groups, respectively (T+S vs PC, P = .001).
From our experience, preoperative chemoembolization combined with short-term systematic chemotherapy is able to achieve higher rates of complete tumor resection and relapse-free survival in the treatment of advanced Wilms tumor.
评估术前经导管动脉化疗栓塞(TACE)联合短期系统化疗治疗晚期 Wilms 肿瘤的疗效。
本研究为回顾性分析,纳入 1995 年至 2007 年在我院治疗的单侧晚期 Wilms 肿瘤患者 66 例,年龄 5 个月至 11 岁(中位数,2.9 岁;男 30 例,女 36 例)。患者的特征为肿瘤最大直径>10cm,或累及主动脉旁淋巴结,或侵犯下腔静脉,或远处转移,或肿瘤组织学呈间变。患者分为三组,20 例行常规术前化疗(PC 组),采用长春新碱、放线菌素 D 和吡柔比星治疗 4 周;21 例行 TACE 组,术前采用碘化油-吡柔比星-长春新碱乳剂行肾动脉化疗栓塞;25 例行术前化疗栓塞联合短期系统化疗(T+S 组)治疗 2 周。
未观察到药物引起的心脏毒性、肾毒性或肝毒性。PC、TACE 和 T+S 组患者的肿瘤均完全切除,分别为 12(65.0%)例、17(80.9%)例和 22(88.0%)例(T+S 组与 PC 组比较,P=.030)。PC、TACE 和 T+S 组的 2 年无复发生存率分别为 65.0%、80.9%和 100.0%(T+S 组与 PC 组比较,P=.001)。
根据我们的经验,术前化疗栓塞联合短期系统化疗治疗晚期 Wilms 肿瘤,能提高肿瘤完全切除率和无复发生存率。